SI-BONE, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 3, 2026, reporting 45,113,087 shares of common stock outstanding as of October 28, 2026.
Key Highlights
- Shares outstanding: The company reported 45,113,087 shares of common stock outstanding as of October 28, 2026.
- Large accelerated filer: According to the filing, SI-BONE is classified as a large accelerated filer under Rule 12b-2 of the Exchange Act.
- Exchange listing: The company's common stock, par value $0.0001 per share, trades on The Nasdaq Global Market under the symbol SIBN, as stated on the cover page.
- Reporting period: The quarterly report covers the period ended September 30, 2026, filed under Commission File Number 001-38701.
- Tariff risk disclosed: The filing identifies "the impact of enacted or proposed tariffs" on the business, including potential effects on gross margins from international product sales and economic uncertainty on demand, as a subject of forward-looking statements.
- Spinopelvic focus: The company disclosed an expectation "that a significant portion of our revenues will be derived from sales of similar products addressing the spinopelvic anatomy."
SI-BONE's Third-Quarter 2026 Filing: Registrant Details and Business Context
SI-BONE, Inc. (NASDAQ:SIBN), a Delaware-incorporated medical device company headquartered at 88 West Plumeria Drive, San Jose, California 95134, submitted its quarterly report covering the period ended September 30, 2026. According to the filing, the company focuses on products addressing the spinopelvic anatomy, and it expects a significant portion of revenues to come from sales in that product area. The company is not classified as a smaller reporting company or an emerging growth company, but rather as a large accelerated filer.
The filing identifies several business-specific risk areas that inform its forward-looking statements. These include the company's ability to retain and grow its sales team, including third-party sales agents, and its reliance on a limited number of suppliers, including sole-source suppliers, which the filing notes "may impact the availability of instruments and materials." The company also disclosed that enacted or proposed tariffs could affect gross margins related to international product sales and may introduce economic uncertainty affecting product demand, according to the filing.
Additional topics addressed in the forward-looking statements section include the company's clinical trial activities, FDA marketing clearances and authorizations, physician identification and training, and coverage and reimbursement determinations from third-party payors. The filing states that forward-looking statements "speak only as of the date of this Quarterly Report" and are subject to risks described under the "Risk Factors" and "Management's Discussion and Analysis" sections. The company cautions that "investors are cautioned not to unduly rely upon these statements."
What Was Disclosed
SI-BONE filed its September 30, 2026 quarterly report on November 3, 2026, disclosing 45,113,087 shares outstanding as of October 28, 2026, its large accelerated filer status, and forward-looking business topics including tariff risks, spinopelvic product revenue concentration, and supplier dependencies.




Please wait processing your request...